A Study of Vonoprazan in Adults With Helicobacter Pylori

Status Completed

Clinical Trial Summary

Helicobacter Pylori (H Pylori) is a bug found in the digestive system. It can cause soreness and redness in the stomach (gastritis). It can also cause ulcers in the stomach and other parts of the digestive system. Vonoprazan is a medicine to treat people with H Pylori. It is taken together with other medicines to fight infections caused by H Pylori. The main aim of this study is to learn if vonoprazan changes how the other medicines are processed by the body. It will be compared with another medicine called esomeprazole. Other aims are to check for side effects from the study medicines. At the first visit, the study doctor will check who can take part. Participants who take part will be picked for 1 of 2 treatments by chance. - Vonoprazan taken with bismuth, clarithromycin, and amoxicillin - Esomeprazole taken with bismuth, clarithromycin, and amoxicillin Both treatments will last for 14 days. Participants will stay in the clinic throughout their treatment. After treatment, the clinic staff will telephone the participants 2 days later for a check-up. The participants will visit the clinic 4 weeks later for a final check-up.

Clinical Trial Description

This is a study in healthy participants with Helicobacter pylori (HP positive) to evaluate the safety, tolerability and PK of a quadruple therapy with bismuth, clarithromycin, amoxicillin, and vonoprazan versus quadruple therapy with bismuth, clarithromycin, amoxicillin, and esomeprazole. The treatment phase consists of quadruple therapy twice daily (BID) with bismuth potassium citrate (600 mg), clarithromycin (500 mg), amoxicillin (1000 mg), and vonoprazan (20 mg) (Group B) or quadruple therapy BID with bismuth potassium citrate (600 mg), clarithromycin (500 mg), amoxicillin (1000 mg), and esomeprazole (20 mg) (Group A) from Days 1 to 14. Participants will be discharged on Day 15 after all procedures have been performed. This single-center will be conducted in China. Participants will remain confined to the study site from check-in (Day -1) through Day 15 and will followed up through call on Day 17 and return on Day 42 for a follow-up assessment. ;

Study Design

Related Conditions & MeSH terms

Helicobacter Pylori

Clinical Trial Details

NCT number	NCT04753437
Study type	Interventional
Source	Takeda
Contact
Status	Completed
Phase	Phase 1
Start date	April 6, 2021
Completion date	November 5, 2021

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02892409` - TAK-438 Bismuth Drug Interaction Study	Phase 1
Completed	`NCT05073367` - A Study Reviewing Medical Records of Adults With Helicobacter Pylori Infections in China
Completed	`NCT00596401` - The Preventive Effect of Helicobacter Pylori Eradication on the Development of Gastric Cancer
Not yet recruiting	`NCT04101708` - A Comparison of High-dose Dual Therapy and Half-dose Clarithromycin-containing Bismuth Quadruple Therapy for H.P Eradication in Elderly Patients	Phase 4
Recruiting	`NCT04029493` - The Situation of Re-infection of Helicobacter Pylori After Successful Eradication
Recruiting	`NCT04030715` - The Associations Between the Gastric Mucosal Pathology and the Eradication Rate of H.Pylori :A Multicenter Study	N/A
Recruiting	`NCT04029415` - The Study of the Antimicrobial Resistance of Helicobacter Pylori in Shandong Province
Not yet recruiting	`NCT02933229` - The Influence of Helicobacter Pylori Eradication on Gastric Pathology: a Long-term, Prospective Cohort Study	Phase 4
Not yet recruiting	`NCT02934048` - Optimal Duration of Antimicrobial Susceptibility Test (AST) Guided Rescue Therapy for Helicobacter Pylori Infection	Phase 4
Recruiting	`NCT05184491` - Nitazoxanide and Lansoprazole Based Regimens for H. Pylori Management	Phase 4
Recruiting	`NCT05790525` - Effect of Oral Helicobacter Pylori Infection on the Efficacy of Gastroluminal Helicobacter Pylori Eradication Therapy	Phase 4
Completed	`NCT05790512` - Association of Oral Helicobacter Pylori Infection With Gastric Helicobacter Pylori Infection
Recruiting	`NCT05276557` - PyloPlus Urea Breath Test System Pediatric Safety and Efficacy Study	Phase 3
Recruiting	`NCT03177629` - H. Pylori Eradication for Moderate ITP	Phase 3
Recruiting	`NCT05053945` - Helicobacter Pylori, Atrophic Gastritis and Intestinal Metaplasia Registry and Prospective Study
Recruiting	`NCT05449028` - Helicobacter Pylori Eradication Therapy in Portugal	N/A
Recruiting	`NCT00306280` - Feasibility Study of Phototherapy System to Treat H Pylori	N/A
Active, not recruiting	`NCT02675010` - Value of Additional Corpus Biopsy for Diagnosis of H Pylori in Atrophic Gastritis. Prospective Non-randomized Study	N/A
Withdrawn	`NCT00467155` - Helicobacter in The Gambia (Part 2)	N/A
Completed	`NCT03716622` - A Comparison of Clarithromycin-based and Furazolidone-based Bismuth-containing Regimens for H. Pylori Eradication	Phase 4

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.